Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The first meeting of the new Pharmacology Public Engagement Committee, which includes academic and research staff as well as students, was held last week. The group had a lively discussion about public engagement activity in the Department, how such activity can be better supported and encouraged within Pharmacology and how members of the committee can act as ambassadors to provide guidance to anyone thinking about engagement. With regard to particular activities, the committee talked about the opportunity for research groups to win an animation about their research produced by Oxford Sparks (apply here); Pharmacology’s plans for IF (the Oxford Science Festival) (see Barbara Zonta if you want to be involved); and opportunities to organise in-house training for anyone thinking about public engagement.

Similar stories

EMA approval of IntraBio’s Aqneursa marks a major milestone for the Department of Pharmacology, with further Phase 3 success in Ataxia Telangiectasia

On 21 January, the European Medicines Agency (EMA) approved Aqneursa, a new treatment for Niemann-Pick Disease Type C (NPC) in adults and children, marking a major milestone for research originating in the Department of Pharmacology. Aqneursa already received US FDA approval (September 2024), enabling patient access on both sides of the Atlantic.